CSL Behring Plans $240 Million Expansion At Its Kankakee, Illinois, Operations Center
According to the firm, its production expansion is designed to meet a growing need for its lifesaving and life-improving therapies, used to treat patients with rare and serious medical disorders around the world.
CSL Behring plans production capacity increases of plasma intermediates at its Kankakee site and albumin at its Broadmeadows facility in Australia. At Kankakee, the expansion will substantially increase the production of plasma intermediates. CSL Behring uses plasma intermediates to make albumin and immunoglobulins. The expansion is expected to be completed in 2017, at which time 300,000 square feet will have been added to the site. Of the $450 million investment, $240 million will be for Kankakee and $210 million for Broadmeadows.
The announcement follows the U.S. Food and Drug Administration's recent regulatory approval to commence operations from a previous expansion of Kankakee's manufacturing operation, which added 140,000 square feet.
The cross-functionality that is enabled by the capacity expansions will allow CSL Behring to leverage its global manufacturing network, helping to optimize the manufacturing efficiencies of immunoglobulin and albumin. “Our latest production expansion means the critical base material for our leading therapies will continue to be available -- enabling us to deliver on our promise to patients around the world," said CEO Paul Perreault.
Beam Therapeutics Selects Research Triangle Park, North Carolina, for Research and Production Campus
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
How are Uncertain Times Altering Company Location Strategies?
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
A Heightened Focus on Reshoring
34th Annual Corporate Survey & the 16th Annual Consultants Survey